blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3209670

EP3209670 - NEW THIENOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.08.2019
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  31.08.2018
FormerGrant of patent is intended
Status updated on  16.05.2018
FormerRequest for examination was made
Status updated on  28.07.2017
FormerThe international publication has been made
Status updated on  14.04.2017
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY, HU, MK		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse / BE
[2018/23]
Former [2017/35]For all designated states
Janssen Pharmaceutica N.V.
Turnhoutseweg 30
2340 Beerse / BE
Inventor(s)01 / HYND, George
8/9 Spire Green CentreFlex Meadow
Harlow Essex CM19 5TR / GB
02 / TISSELLI, Patrizia
8/9 Spire Green Centre Flex Meadow
Harlow Essex CM19 5TR / GB
03 / MACLEOD, Calum
8/9Spire Green CentreFlex Meadow
Harlow Essex CM19 5TR / GB
04 / MANN, Samuel Edward
8/9 Spire Green Centre Flex Meadow
Harlow Essex CM19 5TR / GB
05 / MONTANA, John Gary
8/9 Spire Green CentreFlex Meadow
Harlow Essex CM19 5TR / GB
06 / PRICE, Stephen Colin
8/9 Spire Green CentreFlex Meadow
Harlow Essex CM19 5TR / GB
 [2017/35]
Representative(s)Lenaerts, Philip
Johnson & Johnson Patent Law Department
Turnhoutseweg 30
2340 Beerse / BE
[2017/35]
Application number, filing date15787516.222.10.2015
[2017/35]
WO2015EP74430
Priority number, dateEP2014019007723.10.2014         Original published format: EP 14190077
[2017/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016062789
Date:28.04.2016
Language:EN
[2016/17]
Type: A1 Application with search report 
No.:EP3209670
Date:30.08.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 28.04.2016 takes the place of the publication of the European patent application.
[2017/35]
Type: B1 Patent specification 
No.:EP3209670
Date:03.10.2018
Language:EN
[2018/40]
Search report(s)International search report - published on:EP28.04.2016
ClassificationIPC:C07D519/00, A61K45/06, A61P35/00
[2017/35]
CPC:
C07D519/00 (EP,CN,IL,US); C07D495/04 (IL,KR); A61K31/437 (IL,KR);
A61K31/519 (IL,KR); A61P35/00 (EP,IL,US); C07B2200/05 (CN,IL)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/35]
Extension statesBA23.05.2017
ME23.05.2017
Validation statesMA23.05.2017
TitleGerman:NEUE THIENOPYRIMIDINDERIVATIVE ALS NIK INHIBITOREN[2018/20]
English:NEW THIENOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS[2017/35]
French:NOUVELLES DERIVÉS DE THIENOPYRIMIDINE COMME INHIBITEURS DE NIK[2018/20]
Former [2017/35]NEUE THIENOPYRIMIDINDERIVATE ALS NIK-INHIBITOREN
Former [2017/35]NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE UTILES EN TANT QU'INHIBITEURS DE NIK
Entry into regional phase23.05.2017National basic fee paid 
23.05.2017Designation fee(s) paid 
23.05.2017Examination fee paid 
Examination procedure13.04.2017Date on which the examining division has become responsible
23.05.2017Examination requested  [2017/35]
08.11.2017Amendment by applicant (claims and/or description)
17.05.2018Communication of intention to grant the patent
27.08.2018Fee for grant paid
27.08.2018Fee for publishing/printing paid
27.08.2018Receipt of the translation of the claim(s)
Opposition(s)04.07.2019No opposition filed within time limit [2019/37]
Fees paidRenewal fee
02.11.2017Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.10.2015
AL03.10.2018
AT03.10.2018
CY03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
MK03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SI03.10.2018
SK03.10.2018
SM03.10.2018
TR03.10.2018
LU22.10.2018
MT22.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
[2020/31]
Former [2020/17]AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SI03.10.2018
SK03.10.2018
SM03.10.2018
TR03.10.2018
LU22.10.2018
MT22.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2020/08]AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SI03.10.2018
SK03.10.2018
SM03.10.2018
LU22.10.2018
MT22.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/50]AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SI03.10.2018
SK03.10.2018
SM03.10.2018
LU22.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/40]AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SK03.10.2018
SM03.10.2018
LU22.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/37]AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SM03.10.2018
LU22.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/34]AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
PL03.10.2018
RS03.10.2018
LU22.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/30]AL03.10.2018
AT03.10.2018
CZ03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
PL03.10.2018
RS03.10.2018
LU22.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/26]AL03.10.2018
AT03.10.2018
CZ03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
PL03.10.2018
RS03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/25]AT03.10.2018
CZ03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
PL03.10.2018
RS03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
Former [2019/24]AT03.10.2018
CZ03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
PL03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
Former [2019/23]AT03.10.2018
CZ03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
PL03.10.2018
BG03.01.2019
NO03.01.2019
IS03.02.2019
Former [2019/22]CZ03.10.2018
FI03.10.2018
LT03.10.2018
PL03.10.2018
BG03.01.2019
NO03.01.2019
IS03.02.2019
Former [2019/21]FI03.10.2018
LT03.10.2018
NO03.01.2019
IS03.02.2019
Former [2019/20]LT03.10.2018
NO03.01.2019
Cited inInternational search[AD]WO2009158011  (AMGEN INC [US], et al) [AD] 1-15* page 1, line 1 - page 6, line 4 *;
 [AD]WO2012123522  (HOFFMANN LA ROCHE [CH], et al) [AD] 1-15 * page 1, line 1 - page 1, line 18; example -; claim - *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.